Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZNCF AstraZeneca	$139.69 -2.7%	$140.55	$120.64 ▼ $175.00	N/A	N/A	2,314 shs	821 shs
CSPCY CSPC Pharmaceutical Group	C$3.84 -7.8%	C$3.43	C$2.15 ▼ C$4.62	N/A	N/A	22,672 shs	3,299 shs
DCHPF Dechra Pharmaceuticals	$46.90	$46.90	$30.00 ▼ $47.40	N/A	N/A	1,687 shs	N/A
ORINF Orion Oyj	$48.65	$48.62	$48.65 ▼ $48.65	N/A	N/A	1,080 shs	N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZNCF AstraZeneca	0.00%	-5.64%	-2.49%	-2.60%	-8.10%
CSPCY CSPC Pharmaceutical Group	0.00%	-15.44%	+10.20%	+61.81%	+20.98%
DCHPF Dechra Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ORINF Orion Oyj	0.00%	0.00%	0.00%	0.00%	+3.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZNCF AstraZeneca	0.0827 of 5 stars	0.0	0.0	1.7	0.0	1.3	0.8	0.0
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DCHPF Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORINF Orion Oyj	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZNCF AstraZeneca	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A
DCHPF Dechra Pharmaceuticals	N/A	N/A	N/A
ORINF Orion Oyj	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZNCF AstraZeneca	N/A	N/A	N/A	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A	N/A	N/A	N/A
DCHPF Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
ORINF Orion Oyj	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZNCF AstraZeneca	N/A	$0.82	171.19	∞	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
CSPCY CSPC Pharmaceutical Group	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
DCHPF Dechra Pharmaceuticals	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ORINF Orion Oyj	N/A	$1.61	30.28	∞	N/A	N/A	N/A	N/A	7/18/2025 (Estimated)

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZNCF AstraZeneca	$2.80	2.00%	N/A	343.14%	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A	N/A	N/A
DCHPF Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORINF Orion Oyj	$1.25	2.57%	N/A	77.80%	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZNCF AstraZeneca	40.87%
CSPCY CSPC Pharmaceutical Group	N/A
DCHPF Dechra Pharmaceuticals	N/A
ORINF Orion Oyj	18.76%

Insider Ownership

Company	Insider Ownership
AZNCF AstraZeneca	N/A
CSPCY CSPC Pharmaceutical Group	N/A
DCHPF Dechra Pharmaceuticals	N/A
ORINF Orion Oyj	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZNCF AstraZeneca	83,500	N/A	N/A	Not Optionable
CSPCY CSPC Pharmaceutical Group	23,500	N/A	N/A	Not Optionable
DCHPF Dechra Pharmaceuticals	2,457	N/A	N/A	Not Optionable
ORINF Orion Oyj	3,819	N/A	N/A	Not Optionable

ORINF, AZNCF, CSPCY, and DCHPF Headlines

Recent News About These Companies

ORION Holdings Corp. (ORINF) Q1 2025 Earnings Call Transcript

April 23, 2025 | seekingalpha.com

Orion OYJ (ORINY) Is a Great Choice for 'Trend' Investors, Here's Why

September 26, 2024 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORINF, AZNCF, CSPCY, and DCHPF Company Descriptions

AstraZeneca OTCMKTS:AZNCF

$139.69 -3.91 (-2.72%)

As of 06/20/2025 02:10 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

CSPC Pharmaceutical Group OTCMKTS:CSPCY

C$3.84 -0.33 (-7.81%)

As of 06/20/2025 03:38 PM Eastern

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Dechra Pharmaceuticals OTCMKTS:DCHPF

$46.90 0.00 (0.00%)

As of 01/18/2024

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Orion Oyj OTCMKTS:ORINF

$48.65 0.00 (0.00%)

As of 06/20/2025

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time